Neisseria gonorrhoeae is a strict human pathogen responsible for more than 100 million new 26 sexually transmitted infections worldwide each year. Due to the global emergence of antibiotic 27 resistance, the CDC recently listed N. gonorrhoeae as an urgent threat to public health. No 28 vaccine is available in spite of the huge disease burden and the possibility of untreatable 29 gonorrhea. The aim of this study is to investigate the immunogenicity of a novel whole-cell based 30 inactivated gonococcal microparticle vaccine formulation loaded in dissolvable microneedles for 31 transdermal administration. The nanotechnology-based vaccine formulation consists of 32 inactivated whole-cell gonococci strain CDC-F62, spray dried and encapsulated into 33 biodegradable cross-linked albumin matrix with sustained slow antigen release. The dry vaccine 34 nanoparticles were then loaded in a dissolvable microneedle skin patch for transdermal delivery. 35
ABSTRACT: 25
Neisseria gonorrhoeae is a strict human pathogen responsible for more than 100 million new 26 sexually transmitted infections worldwide each year. Due to the global emergence of antibiotic 27 resistance, the CDC recently listed N. gonorrhoeae as an urgent threat to public health. No 28 vaccine is available in spite of the huge disease burden and the possibility of untreatable 29 gonorrhea. The aim of this study is to investigate the immunogenicity of a novel whole-cell based 30 inactivated gonococcal microparticle vaccine formulation loaded in dissolvable microneedles for 31 transdermal administration. The nanotechnology-based vaccine formulation consists of 32 inactivated whole-cell gonococci strain CDC-F62, spray dried and encapsulated into 33 biodegradable cross-linked albumin matrix with sustained slow antigen release. The dry vaccine 34 nanoparticles were then loaded in a dissolvable microneedle skin patch for transdermal delivery. 35
The efficacy of the whole-cell microparticles vaccine formulation loaded in microneedles was 36 assessed in vitro using dendritic ,cells and macrophages as well as in vivo mouse model. Antibody 37 titers were measured using an ELISA and antigen-specific T lymphocytes were assessed in 38 spleens and lymph nodes. Here we report that whole-cell based gonococcal microparticle vaccine 39 loaded in dissolvable microneedles for transdermal administration induced significant increase in 40 antigen-specific IgG antibody titers and antigen-specific CD4 and CD8 T lymphocytes in mice 41 compared to gonococcal antigens in solution or empty microneedles. Significant increase in 42 antigen-specific IgG antibody levels was observed at end of week 2 in groups that received the 43 vaccine compared to the group receiving empty nanoparticles. The advantages of using formalin-44 fixed whole-cell gonococci that all immunogenic epitopes are covered and preserved from 45 degradation. The spherical shaped micro and nanoparticles are biological mimics of gonococci, 46 therefore present to the immune system as invaders but without the ability to suppress adaptive 47 immunity. In conclusion, the transdermal delivery of microparticles vaccine via a microneedle 48 patch was shown to be an effective system for vaccine delivery. The novel gonorrhea 49 nanovaccine is cheap to produce in a stable dry powder and can be delivered in microneedle skin 50 patch obviating the need for needle use or the cold chain. 51
INTRODUCTION 53
Neisseria gonorrhoeae is strictly a human pathogen that causes sexually transmitted infection. 54
The disease state termed gonorrhea accounts for >100 million cases worldwide each year. The 55 gonococcus (GC) is noted for its capacity to develop resistance to antibiotics used in therapy 56
(1,2). The gonococcus can survive extracellularly and intracellularly, however, in both 57 environments, the bacteria must adapt to pressures exerted by the host (3,4). There were over 58 400,000 reported cases in the US in 2015, and several more that are not reported (1, 2, 5) . It is 59 much more common in Africa and other developing nations (6) . Untreated gonococcal infection 60 in women may progress to pelvic inflammatory disease, increasing the risk of ectopic pregnancy 61 and infertility (7). Currently, there are no vaccines for gonorrhoeae. The main reason to warrant 62 the development of a gonococcal vaccine is the emergence of antibiotic-resistant GC (8). With 63 the development of antibiotic-resistant strains of N. gonorrhoeae, the FDA and CDC have listed 64 the research and development of a vaccine against gonorrhea as a high priority. 65
66
To date, no FDA approved vaccine against gonorrhea is available in spite of the huge burden of 67 disease (9-11). Only two vaccines for N. gonorrhoeae have entered into clinical trials in the past. 68
The first was a crude killed whole-cell vaccine, which was studied in a controlled experiment in a 69 population of Inuit in northern Canada with high incidence and prevalence of N. gonorrhoeae 70 infection (12,13). There was no evidence for protection, even though the vaccine was said to be 71 well tolerated. Although the vaccine induced an antibody response in over 90% of vaccine 72 recipients it lacked the generation of an adaptive immune response which led to the failure of the 73 vaccine study (14) . N. gonorrhoeae can interact with various immune cells to elicit innate 74 inflammatory responses and suppress Th1/Th2-mediated specific immune responses (15) . 75
Phagocytosis by macrophages results in the activation of NLRP3 inflammasomes, the production 76 of IL-1β, activation of PMNs, and activation of cathepsin B, which leads to pyronecrosis of antigen 77 presenting cells (APCs) (16). Interactions with DCs lead to up-regulation of PDL-1 and PDL-2, 78 which induce apoptosis of cells bearing PD-1. This up-regulation also causes the release of IL-79 10, which has immunoregulatory properties and stimulates type 1 regulatory T cells (Treg1) (15) . antibodies that could enhance phagocytosis and intracellular clearance of gonococci by 87 phagocytes and bacteriolysis through the classical complement pathway (4,9,19). 88
89
We developed a novel nanotechnology-based vaccine formulation consisting of formalin fixed 90 whole-cell N. gonorrhoeae as the vaccine antigen encapsulated in biodegradable microparticles 91 loaded in microneedles for transdermal administration. The nanotechnology-based vaccine 92 formulations enhance immune responses by slowly releasing antigens and thereby, act as antigen 93 depot. The advantages of using formalin fixed whole-cell gonococci that all immunogenic epitopes 94 are covered and preserved from degradation; the spherical shaped micro and nanoparticles are 95 biological mimics of gonococci, therefore present to the immune system as invaders but without 96 the ability to suppress adaptive immunity; and less toxicity due to lower antigen loading (10%) in 97 nanoparticles. Here we report that the gonococcal nanovaccine formulation enhanced antibody 98 response and induced antigen-specific CD4 and CD8 T lymphocyte in mice vaccinated with 99 gonococcal nanoparticles loaded in microneedles compared to mice vaccinated subcutaneously 100 with gonococcal antigens in solution or empty microneedles. 101 (22-30). Briefly, for a batch of 100 mg of vaccine microparticles at1% antigen loading, 10 mg of 124 the formalin-fixed whole-cell of N. gonorrhoeae (5 ml of 2 mg/mL stock solution) and 90 mg of pre 125 cross-linked BSA were mixed. Pre-cross-linked BSA solution was prepared by dissolving 90 mg 126 BSA in 5 mL DI water in a 50 mL beaker. Once BSA is dissolved, glutaraldehyde (25% in DI water 127 purchased from Fisher Scientific, Pittsburgh, PA) was added at 200 µL for every 1gm of BSA and 128 kept stirring at 300 rpm overnight in a dark place at room temperature. Excess glutaraldehyde 129 was neutralized with sodium bisulphate (10 mg). At this point, the formalin-fixed whole-cell of N. 130 gonorrhoeae was added to the pre-cross-linked BSA prepared overnight. 100 mg of this prepared 131 formulation was dissolved in 10mL of DI water. This formulation was spray dried through a 0.5 132 mm nozzle (nozzle temperature: -5°C). The inlet temperature was 120°C with the aspirator at 133 100% and a flow rate of 20 mL/h to obtain the N. gonorrhoeae vaccine microparticles. 134
135

Microparticle recovery yield 136
Recovery yield of the microparticles after spray drying was calculated for all the batches 137 formulated (31). Percent recovery yield was evaluated using the following formula: 138
Percentage Recovery Yield (%) = *
139
Particle size distribution 140
The particle size of the optimized formulation was evaluated using the Spectrex Laser 141
Particle Counter that works on the principle of laser diffraction as previously described (25, 32) . 142
Briefly, two mg of the particles were suspended in 1 mL of deionized water, vortexed well, and 143 then analyzed by laser diffraction on the particle counter. Particle size was measured in triplicate 144 for empty as well as antigen-loaded particles and contrasted. 145
146
Zeta potential measurement 147
Five micrograms of microparticles were suspended in 1 mL of deionized water, transferred to a 148 zeta potential measurement cuvette, and measured using a Malvern Zetasizer. Zeta potential was 149 measured in triplicate for the control formulation and contrasted with the antigen-loaded 150 microparticles (33). 151
152
Scanning electron microscopy of the microparticles 153
Scanning electron microscopy (SEM) was performed to evaluate microparticle size distribution 154 and surface morphology. Microparticles were mounted onto metal stubs using double-sided 155 adhesive tape. After being vacuum-coated with a thin layer (100-150Å) of gold, the microparticles 156 were examined by a scanning electron microscope Phenome benchtop SEM, Nanoscience 157
Instruments, Phoenix, AZ. 158
159
Nitric oxide release from DC2.4 cells 160 161
Freshly grown adherent DC2.4 cells were harvested, washed and re-suspended in Dulbecco's 162 complete media, counted and adjusted to 10 6 cell/mL 250 µL aliquots were then dispensed into 163 each well of a 48-well plate at final 250×10 3 cell density prior to stimulation with gonorrhea vaccine 164 microparticles and blank microparticles. The induced cells were incubated overnight at 37°C with 165 5% CO2 and supernatants were harvested. Nitric oxide release was quantified using the Greiss 166 chemical method as previously described (34). Briefly, the Griess chemical method was used to 167 detect nitrite (NO2) accumulated in supernatants of induced RAW264 macrophages. Griess 168 reagent was freshly prepared by mixing equal volumes of 1% sulfanilamide and 0.1% N-(1-169 naphthylethylenediamine) solutions. One hundred microliters of cell supernatants were 170 transferred into a 96-well plate to which 100 µL of Griess reagent was added. The plate was mixed 171 gently, incubated for 10 min at room temperature, and read at 540 nm using a microplate reader 172 (EL312e; BIO-TEK Instruments, Winooski, VT). The optical densities were correlated to the 173 concentration of nitrite. Nitrite was quantitated using the standard curve of sodium nitrite (1 mM 174 stock concentration in distilled water further diluted to the highest standard at 100 µM followed by 175 serial dilutions to 1.56 µM) (34). 176 177 178
Cytotoxicity study 179
The toxicity of the vaccine microparticles toward murine RAW264 macrophages was examined in 180 three replicates by the Alamar Blue assay (20,21). Briefly, 2.5×10 3 cells were plated in each well 181 of a 48 well plate and vaccine microparticles ranging in concentration from 50 µg to 500 µg, with 182 4 replicates for each concentration, were added to each well. Atropine sulfate was used as a 183 positive control at a concentration of 10 mg/ml. The readings were normalized with the blank 184 microparticles. After 24 hours, 10 µl of a 10× solution of Alamar Blue was added to each well and 185 plates were incubated for 4 hours at 37 0 C following which the fluorescence was measured at 585 186 nm using Bio-Tek Synergy H1 plate reader, Winooski, VT. 187
188
Formulation of dissolvable microneedles for transdermal delivery of vaccine particles 189
Dissolvable microneedles encompass the use of polydimethylsiloxane (PDMS) micromolds, 190 which are made from a master structure of microneedles (35). Briefly, PDMS solution (Ellesworth 191 adhesives, WI) was poured onto the stainless steel master structure. The particulate vaccine 192 microneedles were made using the following formula in Table 1 
University's Institutional Committee for the care and Use of Laboratory animals (IACUC). 213
For delivering microparticles via the transdermal route, mice skin on the back was shaved two 214 days prior to vaccination. One day prior to vaccination, the remainder of the hair was treated with 215 Nair Hair removal cream (Ewing, NJ) for 10 minutes and then wiped off with a cotton swab. The 216 vaccine loaded microneedles prepared previously were administered in the skin previously 217 treated. The microneedles patch was applied for 20 minutes which ensured the delivery of the 218 vaccine transdermally. One prime dose (100 µg) at day 0 and two booster doses (100 µg) were 219 given at week 1 and 2 were administered. The mice were monitored and blood samples were 220 collected at every 2-week interval starting from day 0, week 2, 4, 6, 8 and 10. 
Determination of T-cell and B-cell based immune response in lymphatic organs 239
The single cell suspension of the spleens and lymph nodes was made using a 40 µm cell strainer. 240
The viability of the cells was checked using the trypan blue exclusion method by TC10 
Statistical analysis 254
All experiments were performed in quadruplets unless otherwise noted. Mean values ± SD and P 255 value (Student's t-test unpaired, two-tail distribution) was determined individually for all 256 experiments with Microsoft Excel software. A p value of less than 0.05 was considered to be 257 statistically significant. 
RESULTS 260
Characterization of whole-cell formalin fixed N. gonorrhoeae microparticle vaccine loaded 261 in dissolvable microneedles: 262
Physical Characterization of N. gonorrhoea microparticle vaccine 263
The process of fixing whole-cell bacteria using formalin to crosslink bacterial surface structures 264 preserves immunogenic epitopes in their native form, hence not lysed or degraded. In this study, 265 the formalin-fixed whole-cell N. gonorrhoeae was intact in native form as examined using the 266 Phenom ® Desktop scanning electron microscope under 20kV at 7500X ( Figure 1A ). Following 267 spray drying, scanning electron microscopy was also used to observe the particles ( Figure 1B) . 268
The surface morphology of the formulated microparticles was irregular shaped and rough (Figure  269 1B). The different shapes of the microparticles may be helpful for uptake by macrophages (37-270 39). 271
The particle size distribution of novel vaccine microparticle formulations from two different batches 272 of empty particles and N. gonorrhoeae antigen-loaded microparticles was investigated using 273
Spectrex laser counter (Spectrex Corporation). The average size of the particles ranged from 3.5 274 µm ± 1.2 µm. There was no significant difference in size between empty and N. gonorrhoeae 275 loaded vaccine microparticles ~90% of which were between 1-5 µm with an average particle size 276 of 3.65 ± 1.89 µm. The percent yield was found to be 85% after spray drying (N=3 batches, Table  277 2). The loss during microparticle preparation was due to microparticles sticking to the cylinder and 278 cyclone of the spray dryer. The surface charge was found to be 7.1mV + 1.4mV. Zeta potential is 279 indicative of the surface charge of the particle. A high positive or negative charge indicates good 280 stability and suspendability of the particles when reconstituted in media as it avoids agglomeration 281 (21). The zeta potential measurements of empty (unloaded) and antigen-loaded microparticle 282 suspensions in deionized water were in the range of -30 to -35 mV with the mean of -32.65 ± 2.4 283 mV and did not differ significantly from each other (Table 2) . Furthermore, The different shapes 284 of the microparticles did not impact uptake by macrophages (37-39). The uptake of vaccine 285 particles by murine RAW264 macrophages resulted in robust induction of autophagic vacuoles 286 visualized using fluorescence microscopy ( Figure 1C ) compared to unstimulated macrophages 287 ( Figure 1D ). The data suggest that the formulated gonococcal vaccine particles are biological 288 mimics of gonococci that retained potential immune stimulatory activity. 289
The uptake of vaccine microparticles and the innate immune recognition of vaccine antigens was 290 monitored by assessing nitric oxide release from dendritic cells co-incubated with these particles. 291
Nitric oxide (NO) is an innate immune marker which is released after the uptake and processing 292 of the vaccine antigens reflecting antigen recognition and stimulation of dendritic cells. A higher 293 level of NO release indicates a stronger activation of dendritic cells. We observed a significantly 294 higher level of NO released by the dendritic cells exposed to vaccine microparticles when 295 compared to the blank microparticles (Figure 2) . The data suggest that albumin based cross-296 linked polymer matrix used to make the microparticles are not immunogenic and the innate 297 immune responses generated are attributed to N. gonorrhoeae antigen present in the vaccine-298 loaded microparticles. 299
Cytotoxicity study: 300
To assess the cytotoxicity of the formulated vaccine-loaded microparticles on antigen presenting 301 cells, we employed the Alamar Blue assay (20,21). The results of the cytotoxicity study indicated 302 that the formulation was not toxic to murine macrophages RAW264 at doses ranging from 50 to 303 500 µg per well (Figure 3) . The viability of the cell population exposed to different doses of 304 microparticles did not differ significantly from the cell populations not exposed to microparticles 305 indicating that the microparticles were not toxic to the cells (Figure 3) . Atropine sulfate was used 306 as a positive control and as expected revealed a highly decreased viability in comparison to the 307 negative control, i.e. cells alone. The results indicate that gonorrhea vaccine-loaded 308 microparticles are not toxic to macrophages. 309
Characterization of the dissolvable microneedles 310
Scanning electron microscopy was carried out to observe the surface morphology and formation 311 of microneedles. Figure 4 (A-C) shows scanning electron microscopy images of the formulated 312 dissolvable microneedle. For transdermal vaccination using microneedle skin patch ( Figure 4D) , 313 it was important to visualize the microchannels in-order to understand their depth within the skin 314 layers. In order to visualize the microchannels, they were stained with either methylene blue or 315 calcein dye (FluoSpheres® 0.2 μm) and observed by light and confocal microscope respectively 316 ( Figure 4E and D) . For methylene blue staining, full thickness murine skin was freshly excised 317 from the animal and treated with microneedle patch. The microchannels were stained with 1% 318 w/v methylene blue solution for 1 min. Excess stain was wiped with a Kimwipe followed by an 319 alcohol wipe. Stained microchannels were imaged with Canon digital camera. A control was also 320 maintained without microneedle treatment to ensure that untreated skin restores the anatomical 321 structure. Both treated and untreated skin samples were embedded in OCT medium in embedding 322 molds and frozen at -80°C. The frozen skin section was cryo-microtomed transversally using 323 Microm HM505E cryostat (Thermo Scientific) with a thickness of 50μm. These sections were 324 mounted onto glass slides and viewed under the Leica DM750 light microscope using a Leica 325 ICC50HD camera at 10X and 40X magnification ( Figure 4E ). For confocal microscopy, full 326 thickness skin was freshly excised and treated with microneedles as described previously (40,41). 327
The channels were then stained with FluSpheres ® 0.2 μm for 2 minutes. Full-thickness skin 328 sections were mounted on microscope slides and viewed under a Zeiss LSM510 confocal 329 microscope with 10X air objective. An argon laser of 488nm wavelength was used to excite the 330 fluorophore and a band pass filter of 500-550 nm was used ( Figure 4F ). Image J software from 331 National Institute of Health, USA was used to analyze the images. 332
333
Immunogenicity of whole-cell N. gonorrhoeae nanovaccine administered via 334
subcutaneous immunization in mice 335
In order to assess the efficacy of the whole-cell particulate vaccine, 10mg of particles were 336 weighed containing 500µg of the antigen and administered to 6-8 week-old Swiss Webster (CFW) 337
subcutaneously. There were 3 groups in the study, one group receiving the subcutaneous 338 gonorrhea particulate vaccine (GC-MP SubQ), one group receiving subcutaneous gonorrhea 339 vaccine in suspension (GC-susp -500µg) and a negative control group, which received the blank 340 particles (N=6). The study dosing included one prime dose at week zero, followed by two booster 341 doses at weeks 4 and 6. Blood samples were collected prior to prime dose and every 2 weeks 342 after dosing. The antibody levels in the blood were measured using specific indirect ELISA (42). 343
A rise in gonococci specific antibody levels was observed beginning at week 4 in groups that 344 received the vaccine compared to the group receiving blank particles ( Figure 5) . 345 346
Mice immunization study using microneedles for transdermal vaccine delivery 347
Based on the positive results from the pilot study of mice vaccination via the subcutaneous route, 348 the immunogenicity of the formulated gonorrhea nanovaccine in dissolvable microneedle for 349 transdermal delivery was further investigated. Using the immune system of the skin, we delivered 350 the vaccine particles via a microneedle patch. These microneedles were loaded with gonorrhea 351 microparticles vaccine, which was applied into the skin, much like a "band-aid patch" delivering 352 the vaccine into the skin. The study was carried out in [6] [7] [8] (week zero) and two booster doses (week 2 and 4) were administered, and blood samples were 358 collected prior to dosing and every 2 weeks after dosing. The animals were monitored for 10 359 weeks. The antibody was measured as previously described using an ELISA method, which 360 demonstrates significantly higher serum IgG titers in groups receiving the gonorrhea (GC) vaccine 361 when compared to the controls (blank particles and blank microneedles after week 2 ) ( Figure 6) . 362
The group which received the GC vaccine microparticles in microneedles showed significantly 363 higher antibody titers at weeks 6 and 8 compared to other groups, which received the GC vaccine 364 in suspension administered subcutaneously (GC-susp SubQ). Our data demonstrate that the 365 transdermal delivery of a microparticles GC vaccine loaded in microneedle (GC-MP-MN) patch 366 was efficient and effective for vaccine delivery. 367 368
Induction of antigen-specific CD4 and CD8 T lymphocytes 369
Since the gonorrhea microparticle vaccine induced humoral immune responses in mice evidenced 370 by the significant increase in antigen-specific antibody titers, we further investigated whether this 371 vaccine induced antigen-specific T lymphocytes. Briefly, the animals were sacrificed at week 12 372 and the primary and secondary lymphoid organs were extracted (i.e. spleen and lymph node), The CD8+ and CD4+ T-cell populations were found to be elevated in splenocytes of vaccinated 382 mice when compared to naïve and the blank microneedle group (Figure 7) . Again, the transdermal 383 delivery of microparticles GC vaccine via a microneedle patch was shown to be an efficient and 384 effective vaccine delivery method. 385 386 387
DISCUSSION 388
We have developed a biodegradable and biocompatible polymer matrix system for making 389 microparticles loaded with vaccine antigens using the spray drying method (20,21,43,44) . We 390 formulated a sustained release particulate gonococcal vaccine that consists of formalin-fixed 391 inactivated whole-cell gonococci encapsulated in an albumin-based polymer matrix that mimics 392 the chemical conjugation process to a protein carrier; hence elicit a T-cell-dependent immune 393 response. The novel particulate gonorrhea vaccine formulation is delivered transdermally using 394 biodegradable microneedles "skin patch". This novel gonorrhea vaccine skin patch is tested in 395 vivo using mouse model and data demonstrated that transdermal vaccine delivery induced 396 significantly higher levels of humoral and adaptive immune responses i.e. antigen-specific serum 397
IgG and antigen-specific CD4 and CD8 T lymphocytes. The data showed over 90 % of vaccinated subjects developed antigen-specific antibody titers that 477 remained high when measured again after one year. The early seventies experimental 478 gonococcus vaccine did not confer 100% protection as 10% of the vaccinated population 479 experienced repeated gonococcal infections (13). That particular gonococcus vaccine was 480 prepared in broth culture that was incubated with thiomersal as a preservative and left to autolyze 481 at room temperature (12,13). In contrast, our proposed whole-cell gonorrhea vaccine is formalin 482 fixed thus preserved from lysis as demonstrated with scanning EM which suggests that 483 immunogenic epitopes are also preserved from degradation and maintained in their native form. 484
We argue that the use of whole-cell formalin fixed gonococci as a vaccine antigen with preserved 485 epitopes loaded in microparticles and delivered transdermally via microneedles is advantageous 486 over other whole-cell preparations. The dynamics of slow and sustained antigen release using 487 this nanotechnology approach enhances the uptake of antigen and the innate immune responses 488 presented here is a proof-of-concept that requires fine-tuning and optimization of gonorrhea 496 vaccine antigen qualitatively and quantitatively which is the main limitation of our study. 497
498
However, this study demonstrates the potential of this novel nanotechnology-based vaccine skin 499 patch formulation. We argue that the proposed nanovaccine shelf life is expected to be several 500 folds higher than that of conventional vaccines since it is spray dried and kept well protected from 501 moisture. The novel nanovaccine encapsulated with the whole-cell inactivated N. gonorrhoeae 502 incorporated into an albumin-based particulate matrix provides the following advantages: whole-503 cell based vaccine that encompasses all immunogenic epitopes; self-adjuvanted vaccine 504 formulations enhance immunogenicity with the addition of outer membrane proteins and 505 molecules including endotoxin that are TLR ligands; improved uptake by immune cells and slow 506 antigen release, i.e. antigen depot effect; induction of robust autophagy formation that enhances 507 antigen presentation; heat-stable formulation that does not require refrigeration; administration by 508 a microneedle skin patch which is non-invasive; and reduced cost with the elimination of 509 expenditures relating to identification of a single immunogenic epitope, purification and scale-up 510 of the antigen, and individual packaging and refrigeration of ampoules. 511 512 513
CONCLUSION 514
We formulated a novel gonorrhea vaccine consists of biodegradable whole-cell formalin fixed N. 515 gonorrhoeae as antigen encapsulated in microparticles then loaded in microneedle "skin patch" 516 for transdermal vaccine delivery. The novel gonorrhea nanovaccine activity was characterized by 517 in-vitro cell-based studies and in-vivo in mice vaccination pilot study. Our data suggest that we 518 have a potentially functional vaccine that elicited antigen-specific antibody response and antigen-519 
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